THYROID CANCERS

TPX-0046, a next-generation RET inhibitor demonstrated preliminary clinical activity in patients with RET-driven cancers who were treated in the phase 1/2 SWORD-1 clinical trial.

A number of clinical trials have provided evidence of efficacy of combination regimens for the treatment of RET-mutant medullary thyroid cancer. During a virtual Targeted Oncology Case-based Roundtable event, Lori Wirth, MD, discussed the options for a 58-year-old man with RET-mutant medullary thyroid cancer.

Christine Dierks, MD, describes the prognosis of the anaplastic thyroid carcinoma and differentiated thyroid cancer populations.

In advanced medullary thyroid cancer, mortality may be predicted by serum carbohydrate antigen 19.9 (Ca19.9) positivity in patients as well as by doubling times less than 6 months and less than 1 year. Results of a retrospective study suggest that these 2 new prognostic factors should be considered when initiating treatment for patients with MTC.

The rising prevalence of thyroid cancer and thyroid nodules, especially for differentiated thyroid cancer, has brought into question the management of disease as it is known today.

The FDA has granted Breakthrough Therapy Designation to cabozantinib for the potential treatment of patients with differentiated thyroid cancer that has progressed following prior therapy and who are radioactive iodine-refractory if eligible for radioactive iodine.

Steven Sherman, MD, FACE, provides closing thoughts on unmet needs and future directions for the treatment of patients with RAI-refractory DTC.

Approaching patient education of RAI-refractory DTC therapy with lenvatinib, fostering open communication between patients and providers, and monitoring medication adherence.

An expert endocrinologist perspective on managing the toxicities associated with lenvatinib when treating RAI-refractory DTC and the role of dose reduction and interruption.

A review of a multicenter phase 2 study evaluating the safety and efficacy of lenvatinib starting doses in RAI-refractory DTC.

A review of the phase 3 SELECT trial examining the use of lenvatinib for the treatment of RAI-refractory DTC and the management of adverse events.

Steven Sherman, MD, FACE, provides an overview of the history and evolution of treating patients with RAI [radioactive iodine]–refractory differentiated thyroid cancer [DTC].

Steven Sherman, MD, FACE, provides insight on the treatment of radioactive iodine-refractory differentiated thyroid cancer and the management of adverse events.

In an interview with Targeted Oncology, Maria E. Cabanillas, MD, discussed the use of larotrectinib as treatment of patients with thyroid cancer and the pooled findings from 2 larotrectinib trials.

Gallium-68 prostate-specific membrane antigen PET imaging demonstrated the ability to detect metastatic thyroid cancer but resulted in a lower detection rate compared with 2-[18F]FDG PET for thyroid cancer lesion visualization.

Christine Dierks, MD, discusses how PD-L1 expression is used to determine treatment for patients with thyroid cancer.

Patients with tissue tumor mutational burden-high solid tumors represent a subset of patients who could have a robust tumor response to the immune checkpoint inhibitor pembrolizumab as monotherapy, suggesting tTMB may be a novel and useful predictor of response in patients with previously treated recurrent or metastatic advanced solid tumors, including thyroid cancer.

Cabozantinib demonstrated significant improvement in progression-free survival in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after up to 2 prior vascular endothelial growth factor receptor-targeted therapies compared with placebo, meeting the primary end point of the pivotal phase 3 COSMIC-311 clinical trial.

Marcia Brose, MD, PhD, discusses a global, non-interventional study that assessed the use of sorafenib as treatment of patients with asymptomatic radioiodine-refractory differentiated thyroid cancer.

The FDA approved pralsetinib for the treatment of adult and pediatric patients who are 12 years old or older with advanced or metastatic RET-mutant medullary thyroid cancer and require systemic therapy.

Matthew Taylor, MD, reviewed the clinical trials supporting levantinib as a treatment option for a patient with thyroid cancer and discussed the option with a group of oncologists during a Targeted Oncology Case Base Peer Perspectives event.

During a Targeted Oncology Case Based Peer Perspectives event, Marcia S. Brose, MD, PhD, discussed options for a 58-year-old patient with RET-mutant medullary thyroid cancer.

Active surveillance can be a safe and appropriate management strategy for patients with T1aN0M0 low-risk papillary thyroid microcarcinoma, though the decision to use the strategy requires multidisciplinary teams and patient input, according to a new report.

For the majority of patients with medullary thyroid cancer, vandetanib and cabozantinib are both effective treatment options, according to results from a retrospective analysis.

Maria E. Cabanillas, MD, discusses the pooled results of 2 larotrectinib trials for patients with advanced or metastatic TRK fusion-positive thyroid cancer.

The combination of ipilimumab with nivolumab induced an objective response rate of 12% as treatment of patients with thyroid cancer.

In an interview with Targeted Oncology, Marcia Brose, MD, PhD, discussed the findings for the global, non-interventional study that assessed the use of sorafenib as treatment of patients with asymptomatic radioiodine-refractory differentiated thyroid cancer.

Maria E. Cabanillas, MD, discusses the treatment landscape for patients with thyroid cancers harboring a TRK fusion.

Across subsets of patients with thyroid cancer, an interesting collection of research was shared with oncologists during the 2020 European Society of Medical Oncology Virtual Congress, demonstrating improvement in outcomes for patients with thyroid cancers with newer and established approved regimens.

In an interview with Targeted Oncology, Lori J. Wirth, MD, discussed the findings from an analysis of the patient-reported outcomes observed in the LIBRETTO-001 study of selpercatinib in patients with RET-driven thyroid cancers.